
Opinion|Videos|August 7, 2024
Perspectives on Indirect Comparisons of BTK Inhibitors for R/R CLL/SLL
Author(s)Mazyar Shadman, MD, MPH
Mazyar Shadman, MD, MPH, shares comprehensive insights on the latest analyses of zanubrutinib compared with other BTK inhibitors in relapsed/refractory CLL/SLL.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- How do the latest analyses of zanubrutinib compare with other BTK inhibitors in relapsed/refractory CLL/SLL?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
4
Neoadjuvant Pembrolizumab Achieves High pCR Rates in Desmoplastic Melanoma
5



















